53939-77-8

Upstream product

• 13985-43-8 4-hydroxy-3-nitrophenyl benzoate 
• 98-88-4 benzoyl chloride 
• 2444-21-5 (4'-benzyloxyphenyl)benzoate 
• 2444-19-1 4-hydroxyphenyl benzoate 
• 103-16-2 4-Benzyloxyphenol 

Downstream Products

• 53939-60-9 2-Benzoylamino-4-benzoyloxy-phenol 
• 1430330-82-7 N-(1-((6-(7-(2-(4-chlorophenylamino)benzo[d]oxazol-5-yloxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-2-hydroxyacetamide 
• 1430331-47-7 2-(((6-(7-(2-(4-chlorophenylamino)benzo[d]oxazol-5-yloxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-ylamino)-2-oxoethyl acetate 
• 1430330-90-7 N-(4-chlorophenyl)-5-(2-(5-((((1-ethyl-1H-1,2,3-triazol-4-yl)methyl)(isopropyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)benzo[d]oxazol-2-amine 
• 1430331-49-9 N-(4-chlorophenyl)-5-(2-(5-((prop-2-ynylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)benzo[d]oxazol-2-amine 
• 1430330-86-1 4-((6-(7-(2-(4-chlorophenylamino)benzo[d]oxazol-5-yloxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)amino-N-(2-(diethylamino)ethyl)benzamide 
• 1430331-45-5 5-(2-(5-((4-aminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-N-(4-chlorophenyl)benzo[d]oxazol-2-amine 
• 1430331-44-4 tert-butyl 1-((6-(7-(2-(4-chlorophenylamino)benzo[d]oxazol-5-yloxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-ylcarbamate 
• 1430331-42-2 6-(7-(2-(4-chlorophenylamino)benzo[d]oxazol-5-yloxy)thieno[3,2-b]pyridin-2-yl)nicotinaldehyde 
• 1430331-41-1 5-(2-(5-(1,3-dioxolan-2-yl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-N-(4-chlorophenyl)benzo[d]oxazol-2-amine 
• 1430331-39-7 2-(4-chlorophenylamino)benzo[d]oxazol-5-ol 
• 1430331-37-5 2-(4-chlorophenylamino)benzo[d]oxazol-5-yl benzoate 
• 1430330-92-9 1-((6-(7-(2-(4-chlorophenylamino)benzo[d]oxazol-5-yloxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)pyrrolidin-2-one 
• 1430331-35-3 3-(3-(4-Chlorophenyl)thioureido)-4-hydroxyphenyl benzoate 

Relevant academic research and scientific papers

Inhibitors of Protein Tyrosine Kinase Activity

The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

Synthesis and properties of 2-phenylbenzoxazole-based luminophores for in situ photopolymerized liquid-crystal films

We report the synthesis of a series of blue-emitting 2-phenylbenzoxazoles (PBOs) substituted at either the 5- or 6-position of the benzoxazole ring and the para-position of the phenyl substituent. The thermal and optical properties of the materials can be rationalized in terms of the position of the substituent at the benzoxazole moiety and the electron-withdrawing or electron-donating character of the substituents. From the results, we conclude that the combination of an electron-donating substituent at the benzoxazole fragment and an electron-withdrawing one at the phenyl fragment has a more marked effect on the electronic properties of the aromatic PBO core than other possibilities. This particular combination gives luminophores that are suitable for optical applications on the basis of their high emission efficiency and photostability. In view of that, oriented films were prepared by in situ polymerization of a mixture of a liquid crystalline direactive matrix containing 5% (w/w) of the luminophore. The films exhibit linearly polarized emission.